Patritumab Deruxtecan Phase 2 trial unveils encouraging outcomes in metastatic NSCLC
The HERTHENA-Lung01 Phase 2 trial, presented at the 2023 World Conference on Lung Cancer by Daiichi Sankyo, demonstrated that Patritumab Deruxtecan has potential for treating ... Read More